Background
==========

Lung cancer is the highest incidence and mortality of malignant tumors worldwide, and 1.5 million people all over the world die from lung cancer every year \[[@b1-medscimonit-24-7499]\]. Non-small cell lung cancer (NSCLC) accounts for about 85% of all types of lung cancers, and more than 70% of these have advanced diagnosis, and have lost the chance of operative treatment. The 5-year survival rate is less than l5%. The high mortality rate of lung cancer is related to the lack of early detection methods and poor treatment measures \[[@b2-medscimonit-24-7499]--[@b5-medscimonit-24-7499]\]. In order to improve survival rate, we must achieve early diagnosis and surgical treatment. Although a lot of research and exploration have been carried out on the formation and development mechanism of lung cancer, the exact mechanism is not yet clear.

DNA methylation is one of the gene epigenetic modifications that may exist in all higher organisms \[[@b6-medscimonit-24-7499]--[@b8-medscimonit-24-7499]\]. In mammalian body, DNA methylation refers to a reaction of methylation of fifth carbon atoms of cytosine nucleotides (C) to 5 methyl cytosine (5′-mC) under the catalysis of DNA methyltransferase (DNMTs), s-adenosyl methionine as a methyl donor. Methyl cytosine can be converted to thymidine (T) by deamination, resulting in the mutation of C-T and the inactivation of some genes. This process regulates gene expression \[[@b9-medscimonit-24-7499],[@b10-medscimonit-24-7499]\]. DNA methylation often occurs in the CG dinucleotide dense zone, which is called the CpG island \[[@b11-medscimonit-24-7499],[@b12-medscimonit-24-7499]\]. When the CpG sequence of some tumor suppressor genes CpG island is hypermethylation, it can increase the degree of chromosome helix and silencing and deletion of tumor suppressor gene, thereby inducing tumor growth \[[@b13-medscimonit-24-7499],[@b14-medscimonit-24-7499]\]. Increasing evidence illustrates that DNA methylation is involved in the occurrence of tumor, and it is an important biomarker to measure various tumors \[[@b15-medscimonit-24-7499]--[@b17-medscimonit-24-7499]\].

The methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) enzyme takes part in DNA methylation, and regulates the tumoral suppressor genes, thereby affecting the behavior of tumors \[[@b18-medscimonit-24-7499]\]. The MTHFD1 1958G\>A variants, are involved in association with defect of nerve canal and embryonic development, which also is related to various cancers \[[@b19-medscimonit-24-7499]--[@b22-medscimonit-24-7499]\]. Concretely, the genotypes of MTHFD1, including execu1958AA and 1958GA, have a protective effect on the tumor via regulation of DNA methylation \[[@b23-medscimonit-24-7499]\]. Meanwhile, it has been reported that MTHFD1 variant is linked to the risk of lung cancer \[[@b24-medscimonit-24-7499]\]. Nevertheless, the roles of MTHFD1 on proliferation and apoptosis of NSCLC are still unclear.

Herein, we explored the expression levels of MTHFD1 in the LC tissues and cells, and the relationship between MTHFD1 expression and the pathological features and the 5-year survival rate of lung cancer patients. Moreover, we analyzed the roles of MTHFD1 proliferation and apoptosis of NSCLC, and further tested whether the molecular mechanism mediates DNA methylation.

Material and Methods
====================

Tissue source
-------------

The 35 samples of lung cancer tissues and adjacent normal breast tissues were obtained from lung cancer patients who were in The First Affiliated Hospital of Zhejiang Chinese Medical University from May 2015 to April 2017. Patient informed consents were acquired, and all patients agreed that tissues could be applied to our research. The Ethics Committee also approved this study.

Cell culture
------------

Human normal lung epithelial cell line (BEAS-2B) and NSCLC cell lines (A549, NCI-H1299, NCI-H1650, and NCI-H460) were provided from Shanghai Gefan Biotechnology Co., Ltd. Dulbecco's Modified Eagle Medium (DMEM; Haibo, Qingdao, Shandong, China) including 10% fetal bovine serum (FBS; Bena, Beijing, China) and a mixture of penicillin and streptomycin (Yuanmu, Shanghai, China) was used to culture BEAS-2B cells. Roswell Park Memorial Institute 1640 (RPMI-1640; Haibo, Qingdao, Shandong, China) medium supplemented with 10% FBS was used to culture A549, NCI-H1299, NCI-H1650, and NCI-H460 cells. All cells were maintained in an incubator with 95% humidified and 5% CO~2~ (WJ-185I; Santn, Shanghai, China) at 37°C.

RNA interference and transfection
---------------------------------

The human MTHFD1-target siRNA and unspecific scrambled siRNA vectors were synthesized by BioVector (Beijing, China). Then, NCI-H1299 cells were transfected with plasmids by Hieff Trans™ Lipofectamine Reagent (Yeasen, Shanghai, China) for 48 hours.

Quantitative real-time PCR (qRT-PCR)
------------------------------------

First, the tissues and cells of total RNA were harvested and lysed by RNA extraction kit (Promega, Beijing, China). Second, 1 μg of RNA was used to synthesize cDNA by SuperScript^®^ VILO™ cDNA Synthesis kit (Thermo, Shanghai, China) following the manufacturer's instructions. Third, SYBR^®^ Premix Ex Taq™ II kit (Bao biologic engineering, Dalian, Liaoning, China) was used to amply cDNA (Takara, Beijing, China) according to the protocols of the manufacturer. GAPDH was considered as the internal control. The sequences of primers were listed in the [Table 1](#t1-medscimonit-24-7499){ref-type="table"}. The expression level of each gene is quantitatively compared through the 2^−ΔΔCT^ formula.

Western blotting
----------------

The tissues and cells of total proteins were harvested and lysed with high efficiency RIPA lysate (Solarbio, Beijing, China). The contents of proteins were analyzed using protein analyzer (Imagin 200, MD Pacific, Tianjing, China). Each protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The protein was bound to PVDF membranes (Tengxiang; Wenzhou, Zhejiang, China). Then, membranes were transferred to TBST containing 5% skimmed milk powder for 1.5 hours. The corresponding primary antibody was used to incubate the membranes at 4°C refrigerator for 24 hours. (anti-MTHFD1, Abcam, ab18708, dilution: 1: 1000; anti-p53, R&D, IC13551G, dilution: 1: 800; anti-survivin, R&D, IC886G, dilution: 1: 500; anti-Bcl-2 associated X protein (Bax), Abcam, ab32503, dilution: 1: 1000; anti-B-cell lymphoma-2 (Bcl-2), Abcam, ab32370, dilution: 1: 800; anti-DNA methyltransferase 1 (DNMT1), CST, 5032, dilution: 1: 800; anti-DNMT3a, CST, 2160, dilution: 1: 700; anti-DNMT3b, CST, 67259, dilution: 1: 800; anti-GAPDH, R&D, 2275-PC-100, dilution: 1: 1000). Subsequently, membranes were incubated with the secondary antibodies (donkey anti-rabbit IgG, R&D, NL004, 1: 5000; mouse anti-rabbit IgG, CST, 93702, 1: 6000; goat anti-mouse IgG, Abcam, ab6785, 1: 8000) at 37°C for 1 hour. The membranes were exposed by Bio-RAD GelDoc XR+ (V140130, Vedeng, Suzhou, China).

Cell counting kit-8 assay
-------------------------

The viability of NCI-H1299 cells was detected by CCK-8 (Solarbio, Beijing, China) following the manufacturer instructions. First, cells were incubated in 96-well plates (2×10^3^ cell/well) in incubator for 24 hours. Second, cells were respectively exposed to 0.1% PBS (control), unspecific scrambled siRNA vector (empty vector), MTHFD1-target siRNA (MTHFD1-siRNA), and 5-Aza-dc (positive control) for 12, 24, and 48 hours. Third, CCK-8 reagent was added to cells for 4 hours. Absorbance at 450 nm was assessed by SpectraMax iD3 multifunctional enzyme labeling instrument (Molecular Devices, Shanghai, China).

Flow cytometry assay
--------------------

The apoptosis of NCI-H1299 cells was tested using Annexin V-FITC/PI apoptosis detection kit (BestBio, Shanghai, China) as the standardized method. The cells were incubated in 6-well plates (5×10^4^ cell/well) in incubator for 24 hours. Then, the cells were treated as before. Subsequently, the cells were digested by 0.25% trypsin for 2 minutes (Kete, Jiangsu, China). The supernatant was removed, and the cells were resuspended using incubation buffer. The Annexin V-FITC and propidium iodide (PI) were dripped into cells in the dark at room temperature for 25 minutes. BD FACS Aria III flow cytometry (H143461, Huan Xi, Shanghai, China) was used to analyze the cell apoptosis.

Statistical analysis
--------------------

The samples were analyzed in triplicate, and each experiment was conducted at least 3 times. All experimental data was presented as mean ± SD. One-way ANOVA was used to compare the differences between groups. Chi-square test was performed to evaluate the correlation between the expression of MTHFD1 and the clinicopathological features of patients diagnosed with lung cancer. The value of *P*\<0.05 was considered a significant difference.

Results
=======

High expression of MTHFD1 was associated with the progress of lung cancer
-------------------------------------------------------------------------

To study the influence of MTHFD1 in lung tumor, qRT-PCR and western bolt assays were performed. As the qRT-PCR and western blot results showed, the mRNA and proteins levels of MTHFD1 in tumor tissues were significantly higher compared to adjacent normal tissues ([Figure 1A, 1B](#f1-medscimonit-24-7499){ref-type="fig"}). At the same time, the mRNA and proteins levels of MTHFD1 in human normal lung epithelial cell line (BEAS-2B) were lower compared to NSCLC cell lines (A549, NCI-H1299, NCI-H1650, and NCI-H460) ([Figure 1D, 1E](#f1-medscimonit-24-7499){ref-type="fig"}, *P*\<0.05). In addition, our data revealed that the survival percent of lung tumor patients with MTHFD1 high expression was lower than that of MTHFD1 low expression. Meanwhile, the survival time of patients with high MTHFD1 expression was shorter than those with low MTHFD1 expression ([Figure 1C](#f1-medscimonit-24-7499){ref-type="fig"}, *P*=0.0054). In addition, the chi-square test results observed that the expression level of MTHFD1 was linked to tumor size, TNM stage, histologic grade, and metastasis, but it was not linked to gender and age ([Table 2](#t2-medscimonit-24-7499){ref-type="table"}).

si-MTHFD1 represses cell viability and promotes apoptosis in NCI-H1299 cells
----------------------------------------------------------------------------

To interfere with the MTHFD1 gene in NCI-H1299 cells, the transfection efficiency of MTHFD1 was validated by qRT-PCR and western blot. The qRT-PCR data found that when cells were transfected with MTHFD1-siRNA vector, the mRNA level of MTHFD1 was markedly downregulated, compared to empty vector ([Figure 2A](#f2-medscimonit-24-7499){ref-type="fig"}, *P*\<0.05). Meanwhile, the expression trend of MTHFD1 protein was consistent with the expression trend of MTHFD1 mRNA in cells that was transfected with MTHFD1-siRNA vector ([Figure 2B](#f2-medscimonit-24-7499){ref-type="fig"}, *P*\<0.05).

The viability of NCI-H1299 cells was analyzed by CCK-8. The results revealed that 5-Aza-dc obviously decreased cell viability in time-dependent manner. In the same way, si-MTHFD1 also conspicuously reduced the viability of NCI-H1299 cells in time-dependent manner ([Figure 2C](#f2-medscimonit-24-7499){ref-type="fig"}, *P*\<0.05). Additionally, the cell apoptosis was assessed by flow cytometry. As flow cytometry data revealed, si-MTHFD1 and 5-Aza-dc apparently increased the apoptosis rate of NCI-H1299 cells ([Figure 2D](#f2-medscimonit-24-7499){ref-type="fig"}, *P*\<0.05).

si-MTHFD1 regulated the expression of apoptosis-associated factors
------------------------------------------------------------------

In order to examine the apoptosis mechanism of MTHFD1 in NCI-H1299 cells, the levels of p53, survivin, Bax, and Bcl-2 were evaluated using qRT-PCR and western blot analysis. Our qRT-PCR results observed that si-MTHFD1 and 5-Aza-dc dramatically enhanced the mRNA levels of p53 and Bax, whereas attenuating survivin and Bcl-2 mRNA levels ([Figure 3A--3D](#f3-medscimonit-24-7499){ref-type="fig"}, *P*\<0.05). Moreover, in comparison with empty vector, the protein levels of p53 and Bax in MTHFD1-siRNA and 5-Aza-dc were remarkably upregulated, and survivin and Bcl-2 levels were downregulated ([Figure 3E](#f3-medscimonit-24-7499){ref-type="fig"}, *P*\<0.05).

si-MTHFD1 downregulated DNA methylation level in NCI-H1299 cells
----------------------------------------------------------------

To explore the molecular mechanism of MTHFD1 in NCI-H1299 cells, the mRNA and protein levels of DNMT1, DNMT3a and DNMT3b were detected by qRT-PCR and western blot analysis. The qRT-PCR data showed that si-MTHFD1 and 5-Aza-dc significantly suppressed the expression of DNMT1, DNMT3a and DNMT3b ([Figure 4A--C](#f4-medscimonit-24-7499){ref-type="fig"}, *P*\<0.05). Meanwhile, the expression tendency of DNMT1, DNMT3a and DNMT3b proteins in si-MTHFD1 and 5-Aza-dc was similar to the mRNA expression tendency of DNMT1, DNMT3a and DNMT3b ([Figure 4D](#f4-medscimonit-24-7499){ref-type="fig"}, *P*\<0.05).

Discussion
==========

According to a large number of reports, it has been found that the MTHFD1 polymorphisms are related to the risk of various cancers \[[@b25-medscimonit-24-7499]--[@b27-medscimonit-24-7499]\]. Specifically, MTHFD1 G401A is linked to decrease risk of colon tumor, and MTHFD1 G1958A has protective effect on the lymphoblastic leukemia \[[@b27-medscimonit-24-7499]\] and head and neck squamous tumors \[[@b26-medscimonit-24-7499]\]. In addition, Jin et al. have found that MTHFD1 rs1950902 G\>A is obviously related to with poor prognosis of NSCLC \[[@b28-medscimonit-24-7499]\]. Hence, we suspected that MTHFD1 might be highly expressed in the lung cancer and be linked to the unfavorable prognosis of lung cancer. Our results showed that the expression levels of MTHFD1 in tumor tissues and cells were significantly higher than that of adjacent normal tissues and cells. In addition, MTHFD1 expression was associated with tumor size, TNM stage, histologic grade, and metastasis, but not related to gender and age. The survival time of patients with high MTHFD1 expression was shorter than that of lower expression. It was confirmed that high expression of MTHFD1 was relate to the progression of lung cancer.

It is well known that antitumor drugs and related genes generally inhibit the growth of cancer cells and promote apoptosis. Proliferation and apoptosis are 2 important processes of tumor development \[[@b29-medscimonit-24-7499]--[@b32-medscimonit-24-7499]\]. Yang et al. have confirmed that MTHFD1L silencing can repress viability of esophageal squamous cancer cells and expedite apoptosis \[[@b33-medscimonit-24-7499]\]. At present, there is no report on the effect of MTHFD1 on the proliferation and apoptosis of NSCLC cells. We supposed that silence of MTHFD1 might decrease proliferation and increase apoptosis of NSCLC cells. Not surprisingly, our data revealed that si-MTHFD1 predominantly suppressed the viability of NCI-H1299 cells and promoted apoptosis. Hence, it was suggested that MTHFD1 silencing could repress proliferation and induce apoptosis of NSCLC.

Subsequently, the apoptosis mechanism of si-MTHFD1 in NCI-H1299 cells was investigated by detecting the apoptosis-related factors, including p53, survivin, Bax, and Bcl-2. Samarakoon et al. showed that triterpenoid saponin significantly facilitated the apoptosis of NSCLC cells via enhancing p53 and Bax expression and decreasing survivin levels \[[@b34-medscimonit-24-7499]\]. Another study revealed that miR-145 upregulation promoted the apoptosis of NSCLC cells through augmenting the Bax/Bcl-2 ratio \[[@b35-medscimonit-24-7499]\]. Homoplastically, our results showed that si-MTHFD1 notably enhanced the levels of p53 and Bax, whereas it reduced survivin and Bcl-2 levels in NCI-H1299 cells. This phenomenon explained si-MTHFD1 induced apoptosis of NSCLC cells by upregulating p53 and Bax expression, and downregulating survivin and Bcl-2 expression.

A recent study elucidated that the MTHFD1 1958GG genotype markedly decreased the risks of liver and colon tumors through associating with DNA hypomethylation \[[@b23-medscimonit-24-7499]\]. Therefore, we considered that the role of si-MTHFD1 in proliferation and apoptosis of NSCLC cells was by mediating DNA methylation. DNMTs play an important role in the initial methylation and maintenance of methylation. DNMT1 is responsible for accurately replicating the DNA methylation form, playing the role of maintaining methylation \[[@b36-medscimonit-24-7499]\]. DNMT3a and DNMT3b are mainly responsible for the methylation of non-methylated CpG sites \[[@b37-medscimonit-24-7499],[@b38-medscimonit-24-7499]\]. Herein, our results found that si-MTHFD1 drastically inhibited the expression of DNMT1, DNMT3a, and DNMT3b in NCI-H1299 cells. These results suggest that si-MTHFD1 repressed DNA methylation in NSCLC.

Conclusions
===========

Our study results proved that the silence of MTHFD1 could decrease proliferation and enhance apoptosis of NSCLC via suppressing DNA methylation. This study provides a theoretical basis for further exploring the influence of lung cancer *in vitro*. Furthermore, MTHFD1 may be a target for the treatment of lung cancer.
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![High expression of MTHFD1 associates with the progression of lung cancer. (**A**) The mRNA expression of MTHFD1 in lung tumor and adjacent normal tissues was analyzed by qRT-PCR assay. (**B**) The protein expression of MTHFD1 in lung tumor and adjacent normal tissues was assessed by western blot. (**C**) The correlation between MTHFD1 expression and the survival percent of the patients was quantified using GraphPad prism 7. (**D**) The mRNA levels of MTHFD1 in BEAS-2B, A549, NCI-H1299, NCI-H1650, and NCI-H460 cells were tested by qRT-PCR assay. (**E**) The protein level of MTHFD1 in cells was evaluated by western blot. GAPDH was considered as an internal control. The quality one was performed to measure and calculate the gray value. \* *P*\<0.05; \*\* *P*\<0.01, versus BEAS-2B.](medscimonit-24-7499-g001){#f1-medscimonit-24-7499}

![si-MTHFD1 represses cell viability and promotes apoptosis in NCI-H1299 cells. (**A**) NCI-H1299 cells were respectively treated with 0.1%PBS (control), human unspecific scrambled siRNA vector (empty vector), and MTHFD1-target siRNA (MTHFD1-siRNA) vector. The mRNA level of MTHFD1 was tested by qRT-PCR analysis. (**B**) The protein expression of MTHFD1 was examined by western blot. \* *P*\<0.05; \*\* *P*\<0.01, versus empty vector. (**C**) NCI-H1299 cells were respectively exposed to 0.1%PBS (control), human unspecific scrambled siRNA vector (empty vector), MTHFD1-target siRNA (MTHFD1-siRNA) vector, and 5-Aza-dc (positive control). CCK-8 was carried out to assess cell viability for 12, 24, and 48 hours. \* *P*\<0.05, versus 12-hour empty vector. ^\#^ *P*\<0.05, versus 24-hour empty vector. ^@^ *P*\<0.05, ^\$^ *P*\<0.01, versus 48-hour empty vector. (**D**) Annexin V-FITC/PI apoptosis detection kit was used to determine the cell apoptosis. \* *P*\<0.05, \*\* *P*\<0.01, versus control. ^@^ *P*\<0.05, ^\$^ *P*\<0.01, versus empty vector.](medscimonit-24-7499-g002){#f2-medscimonit-24-7499}

![si-MTHFD1 regulates the expression of apoptosis-associated factors. (**A--D**) qRT-PCR was carried to examine the mRNA levels of p53 (**A**), survivin (**B**), Bax (**C**), and Bcl-2 (**D**). (**E**) Western blot was used to assess the protein levels of p53 (**Ea**), survivin (**Eb**), Bax (**Ec**), and Bcl-2 (**Ed**). \* *P*\<0.05, \*\* *P*\<0.01, versus control. ^@^ *P*\<0.05, ^\$^ *P*\<0.01, versus empty vector.](medscimonit-24-7499-g003){#f3-medscimonit-24-7499}

![si-MTHFD1 downregulates DNA methylation level in NCI-H1299 cells. (**A--C**) qRT-PCR was performed to examine the mRNA expression of DNMT1 (**A**), DNMT3a (**B**), and DNMT3b (**C**). (**D**) Western blot was used to evaluate the protein expression of DNMT1 (**Da**), DNMT3a (**Db**), and DNMT3b (**Dc**). (\* *P*\<0.05, \*\* *P*\<0.01, versus control. ^@^ *P*\<0.05, ^\$^ *P*\<0.01, versus empty vector.](medscimonit-24-7499-g004){#f4-medscimonit-24-7499}

###### 

Sequences of the primers.

  Primer name        Sequence (5′-3′)       Product size (bp)
  ------------------ ---------------------- -------------------
  MTHFD1-Forward     AAAGAGAGGGCGAGCTTCAT   
  MTHFD1-Reverse     CCTCTTCAGACAGCAGACCA   250
  p53-Forward        GCCCCTCCTCAGCATCTTAT   
  p53-Reverse        AAAGCTGTTCCGTCCCAGTA   246
  survivin-Forward   TTCTCAAGGACCACCGCATC   
  survivin-Reverse   GTTTCCTTTGCATGGGGTCG   206
  Bax-Forward        AACATGGAGCTGCAGAGGAT   
  Bax-Reverse        CCAATGTCCAGCCCATGATG   208
  Bcl-2-Forward      TTCTTTGAGTTCGGTGGGGT   
  Bcl-2-Reverse      CTTCAGAGACAGCCAGGAGA   207
  DNMT1-Forward      ACTGGCTTTGATGGAGGTGA   
  DNMT1-Reverse      ACCGTGGTCTCGATCTTGTT   206
  DNMT3a-Forward     TCTCCAAGTCCCCATCCATG   
  DNMT3a-Reverse     CAGCCATTTTCCACTGCTCT   193
  DNMT3b-Forward     TTGCTGTTGGAACCGTGAAG   
  DNMT3b-Reverse     TCCTTGGGGCGTGAGTAATT   226
  GAPDH-Forward      CCATCTTCCAGGAGCGAGAT   
  GAPDH-Reverse      TGCTGATGATCTTGAGGCTG   222

###### 

Correlation between the expression of MTHFD1 and the clinicopathological features of lung carcinoma patients.

  Features           Number of patients   Low MTHFD1 expression   High MTHFD1 expression   *P* value
  ------------------ -------------------- ----------------------- ------------------------ -----------------------------------------------------------
  Gender                                                                                   0.784
   Male              26                   10 (76.9%)              16 (72.7%)               
   Female            9                    3 (23.1%)               6 (27.3%)                
  Age(years)                                                                               0.229
   \<60              16                   6 (35.3%)               10 (66.7%)               
   ≥60               19                   11 (64.7%)              5 (33.3%)                
  Tumor size (cm)                                                                          0.002[\*](#tfn1-medscimonit-24-7499){ref-type="table-fn"}
   \<5               15                   10 (76.9%)              5 (22.7%)                
   ≥5                20                   3 (23.1%)               17 (77.3%)               
  TNM stage                                                                                0.011[\*](#tfn1-medscimonit-24-7499){ref-type="table-fn"}
   I/II              10                   7 (53.8%)               3 (13.6%)                
   III/IV            25                   6 (46.2%)               19 (86.4%)               
  Histologic grade                                                                         0.048[\*](#tfn1-medscimonit-24-7499){ref-type="table-fn"}
   Well              3                    2 (13.3%)               1 (5%)                   
   Moderate          12                   8 (53.3%)               4 (20%)                  
   Poor              20                   5 (33.3%)               15 (75%)                 
  Metastasis                                                                               0.024[\*](#tfn1-medscimonit-24-7499){ref-type="table-fn"}
   No                23                   15 (83.3%)              8 (47.1%)                
   Yes               12                   3 (16.7%)               9 (52.9%)                

*P*\<0.05, Chi-square test.
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